BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 06, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

Mifamurtide regulatory update

IDM said that after a meeting with EMEA's CHMP and Secretariat the company now expects an opinion from CHMP on its MAA for mifamurtide (L-MTP-PE) to treat non-metastatic, resectable osteosarcoma...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >